

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM733772

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Eiger Biopharmaceuticals, Inc.		06/01/2022	Corporation: DELAWARE
EB Pharma, LLC		06/01/2022	Limited Liability Company: DELAWARE
EBPI Merger, Inc.		06/01/2022	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Innovatus Life Sciences Lending Fund I, LP		
<b>Street Address:</b>	777 Third Avenue, 25th Floor		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10017		
<b>Entity Type:</b>	Limited Partnership: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90087464	EIGER ONECARE	
<b>Serial Number:</b>	90087462	EIGERONECARE	
<b>Serial Number:</b>	90005739	ZOKINVY	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3059615812		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	3055790812		
<b>Email:</b>	marcosm@gtlaw.com		
<b>Correspondent Name:</b>	Manuel R. Valcarcel		
<b>Address Line 1:</b>	333 S.E. 2nd Avenue, 44th Floor		
<b>Address Line 2:</b>	Greenberg Traurig, P.A.		
<b>Address Line 4:</b>	Miami, FLORIDA 33131		
<b>NAME OF SUBMITTER:</b>	Manuel Valcarcel, Esq.		
<b>SIGNATURE:</b>	/Manuel Valcarcel/		
<b>DATE SIGNED:</b>	06/10/2022		
<b>Total Attachments: 11</b>			

CH \$90.00 90087464

source=IP Security Agreement Eiger June 1 2022#page1.tif  
source=IP Security Agreement Eiger June 1 2022#page2.tif  
source=IP Security Agreement Eiger June 1 2022#page3.tif  
source=IP Security Agreement Eiger June 1 2022#page4.tif  
source=IP Security Agreement Eiger June 1 2022#page5.tif  
source=IP Security Agreement Eiger June 1 2022#page6.tif  
source=IP Security Agreement Eiger June 1 2022#page7.tif  
source=IP Security Agreement Eiger June 1 2022#page8.tif  
source=IP Security Agreement Eiger June 1 2022#page9.tif  
source=IP Security Agreement Eiger June 1 2022#page10.tif  
source=IP Security Agreement Eiger June 1 2022#page11.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of June 1, 2022 (the “**Effective Date**”) by and between INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership as collateral agent for the Lenders (the “**Lenders**”) described in the Loan Agreement (in such capacity, the “**Collateral Agent**”) and EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“**Parent**”), EB Pharma, LLC, a Delaware limited liability company (“**EB Pharma**”), and EBPI MERGER, INC., a Delaware corporation (“**EBPI**” and together with Parent and EB Pharma, individually and collectively, jointly and severally, the “**Grantor**”).

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Intellectual Property constituting Collateral to secure the Obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property constituting Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof constituting Collateral.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies. To the extent there is any conflict between the terms of this Intellectual Property Security Agreement and the Loan Agreement, the Loan Agreement shall control.

This Intellectual Property Security Agreement and the rights and obligations of the parties hereunder shall be governed by and construed in accordance with the laws of the State of New York.

*[Balance of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:  
2155 Park Blvd.  
Palo Alto, CA 94306  
Attn: Sri Ryali  
EMAIL: sryali@eigerbio.com

GRANTOR:

EIGER BIOPHARMACEUTICALS, INC.

By: David Cory  
Name: David A. Cory  
Title: President

EB PHARMA, LLC

By: David Cory  
Name: David A. Cory  
Title: President

EBPI MERGER, INC.

By: David Cory  
Name: David A. Cory  
Title: President

[Signature Page to IP Security Agreement]

**TRADEMARK**  
**REEL: 007748 FRAME: 0261**

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

Address of Grantor:  
2155 Park Blvd.  
Palo Alto, CA 94306  
Attn: Sri Ryali  
EMAIL: sryali@eigerbio.com

GRANTOR:

EIGER BIOPHARMACEUTICALS, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

EB PHARMA, LLC

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

EBPI MERGER, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address of Lender:

777 Third Avenue, 25th Floor  
New York, NY 10017  
Attn: Claes Ekstrom  
Email: cekstrom@innovatuscp.com

COLLATERAL AGENT:

INNOVATUS LIFE SCIENCES LENDING  
FUND I, LP

By: Innovatus Life Sciences GP, LP  
Its: General Partner


By:  \_\_\_\_\_  
Name: Andrew Dym  
Title: Authorized Signatory

EXHIBIT A

**COPYRIGHTS**

None.

EXHIBIT B

**PATENTS**

No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
1.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	Australia	2019359807	1-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
2.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	Brazil	BR112021006 968-2	12-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
3.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	Canada	3115527	6-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
4.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	Chile	CL00892-2021	12-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
5.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	China	201980068180 .8	15-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
6.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	European Union	19873113.5	14-MAY-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
7.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	India	202117020698	6-MAY-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
8.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	Israel	282059	5-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
9.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	Japan	2021-545283	14-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
10.	Avexitide for the treatment of hyperinsulinemic hypoglycemia.	USA	17285039	13-APR-2021	Colleen M. Craig et al	Eiger BioPharmaceuticals, Inc.	Pending
11.	Buffered formulations of Exendin (9-39).	Australia	2017361539	19-JUN-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
12.	Buffered formulations of Exendin (9-39).	Brazil	BR1120190102 36-1	20-MAY-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending

No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
13.	Buffered formulations of Exendin (9-39).	Canada	3043899	14-MAY-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
14.	Buffered formulations of Exendin (9-39).	Chile	CL 01366-2019	20-MAY-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
15.	Buffered formulations of Exendin (9-39).	China	201780078743. 2	19-JUN-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
16.	Buffered formulations of Exendin (9-39).	European Union	17871296.4	21-JUN-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
17.	Buffered formulations of Exendin (9-39).	Hong Kong	62020003841.7	06-MAR-2020	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
18.	Buffered formulations of Exendin (9-39).	India	20191702094 4	27-MAY-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
19.	Buffered formulations of Exendin (9-39).	Israel	266568	12-MAY-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
20.	Buffered formulations of Exendin (9-39).	Japan	2019-527188	20-MAY-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
21.	Buffered formulations of Exendin (9-39).	USA	11020484 16461329	01-JUN-2021 15-MAY-2019	Xiaofeng, Xiong	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Granted
22.	Buffered formulations of Exendin (9-39).	USA	17306782	03-MAY-2021	Xiaofeng, Xiong	Eiger BioPharmaceuticals, Inc. and The Board of Trustees of the Leland Stanford Junior University.	Pending
23.	Combination therapy and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	Australia	2018375298	8-MAY-2020	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
24.	Combination therapy and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	Canada	3082178	7-MAY-2020	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
25.	Combination therapy and pharmaceutical compositions for the	China	201880076561 .6	27-MAY-2020	David Cory	Eiger BioPharmaceuticals, Inc.	Pending

No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
	treatment of non-alcoholic steatohepatitis.						
26.	Combination therapy and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	European Union	18883621.7	26-JUN-2020	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
27.	Combination therapy and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	Japan	2020-546307	27-MAY-2020	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
28.	Method of treating laminopathies.	USA	17699725	--	Richard Anthony Franco Jr. et al	Eiger BioPharmaceuticals, Inc.	Pending
29.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	China	201780065451.5	23-APR-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc.	Pending
30.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	European Union	17857443.0	18-MAR-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc.	Pending
31.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	Hong Kong	62020002206.4	4-FEB-2020	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc.	Pending
32.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	Japan	7022136 2019-538108	17-FEB-2021 18-MAR-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc.	Granted
33.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	S. Korea	10-2019-7011062	17-APR-2019	Xiaofeng Xiong et al	Eiger BioPharmaceuticals, Inc.	Pending
34.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	USA	10588880 16335662	17-MAR-2020 21-MAR-2019	Xiaofeng, Xiong et al	Eiger BioPharmaceuticals, Inc.	Granted
35.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	USA	16781971	04-FEB-2020	Xiaofeng, Xiong	Eiger BioPharmaceuticals, Inc.	Pending
36.	Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis.	USA	16768000	28-MAY-2020	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
37.	Pharmaceutical compositions comprising	China	ZL2016800234 13.9 201680023413.	01-DEC-2020 21-APR-2016	Patrick Gosselin et al	Eiger BioPharmaceuticals, Inc.	Granted



No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
	lonafarnib and ritonavir.		9				
38.	Pharmaceutical compositions comprising lonafarnib and ritonavir.	European Union <sup>1</sup>	EP3285768 16783855.6	30-DEC-2020 21-APR-2016	Patrick Gosselin et al	Eiger BioPharmaceuticals, Inc.	Granted
39.	Pharmaceutical compositions comprising lonafarnib and ritonavir.	Japan	2017-555331	21-APR-2016	Patrick Gosselin et al	Eiger BioPharmaceuticals, Inc.	Pending
40.	Pharmaceutical compositions comprising lonafarnib and ritonavir.	S. Korea	10-2017- 7033536	21-APR-2016	Patrick Gosselin et al	Eiger BioPharmaceuticals, Inc.	Pending
41.	Pharmaceutical compositions comprising lonafarnib and ritonavir.	USA	10835496 15567444	17-NOV-2020 18-OCT-2017	Patrick Gosselin et al	Eiger BioPharmaceuticals, Inc.	Granted
42.	Pharmaceutical compositions comprising lonafarnib and ritonavir.	USA	17073920	19-OCT-2020	Patrick Gosselin et al	Eiger BioPharmaceuticals, Inc.	Pending
43.	Sarpogrelate in therapies for pulmonary hypertension	USA	63243556	13-SEP-2021	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
44.	Sarpogrelate in therapies for secondary Raynaud's disease.	USA	63243591	13-SEP-2021	David Cory	Eiger BioPharmaceuticals, Inc.	Pending
45.	Treatment of cancers.	USA	63266707	12-JAN-2022	David Apelian et al	Eiger BioPharmaceuticals, Inc.	Pending
46.	Methods to treat hepatitis delta viral infections.	Australia	2020368402	1-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
47.	Methods to treat hepatitis delta viral infections.	Brazil	BR112022006 913-8	11-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
48.	Methods to treat hepatitis delta viral infections.	Canada	3156679	1-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
49.	Methods to treat hepatitis delta viral infections.	China	202080072840 .2	18-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
50.	Methods to treat hepatitis delta viral infections.	Israel	291780	29-MAR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
51.	Methods to treat hepatitis delta viral infections.	Japan	2022-522957	15-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
52.	Methods to treat hepatitis delta viral infections.	Mexico	MX/A/2022/004 399	11-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
53.	Methods to treat hepatitis delta viral infections.	Russian Federation	2022108826	4-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
54.	Methods to treat hepatitis delta viral infections.	S. Africa	2022/04021	8-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
55.	Methods to treat hepatitis delta viral infections.	Ukraine	A202201069	1-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending

<sup>1</sup> EP3285768 has been validated or is in the process of being validated in the following countries: Austria, Belgium, Bulgaria, Switzerland, Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, Hungary, Italy, Romania, Sweden, and Turkey.

No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
56.	Methods to treat hepatitis delta viral infections.	USA	17754587	06-APR-2022	Jeffrey Glenn et al	Eiger BioPharmaceuticals, Inc.	Pending
57.	Treatment of hepatitis delta virus infection.	China	ZL2015800235 85.1 201580023585. 1	28-FEB-2020 01-MAY-2015	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
58.	Treatment of hepatitis delta virus infection.	China	202010069655. X	21-JAN-2020	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
59.	Treatment of hepatitis delta virus infection.	European Union2	EP3137078 15785846.5	20-MAR-2019 01-MAY-2015	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
	Treatment of hepatitis delta virus infection.	European Union	19162000.4	01-MAY-2015	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
60.	Treatment of hepatitis delta virus infection.	Japan	6490800 2017-510458	27-MAR-2019 01-MAY-2015	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
61.	Treatment of hepatitis delta virus infection.	S. Korea	10-2016- 7033817	01-MAY-2015	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
62.	Treatment of hepatitis delta virus infection.	China	201680073916 .7	26-OCT-2016	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
63.	Treatment of hepatitis delta virus infection.	European Union3	EP3370723 16862727.1	16-DEC-2020 26-OCT-2016	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
64.	Treatment of hepatitis delta virus infection.	European Union	20214179.2	15-DEC-2020	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
65.	Treatment of hepatitis delta virus infection.	Japan	2018-542682	26-OCT-2016	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
66.	Treatment of hepatitis delta virus infection.	S. Korea	10-2018- 7014733	26-OCT-2016	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
67.	Treatment of hepatitis delta virus infection.	USA	10076512 15335327	18-SEP-2018 26-OCT-2016	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
68.	Treatment of hepatitis delta virus infection.	USA	10828283 16052386	10-NOV-2020 01-AUG-2018	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
69.	Treatment of hepatitis delta virus infection.	USA	11311519 16996147	26-APR-2022 18-AUG-2020	David Cory et al	Eiger BioPharmaceuticals, Inc.	Granted
70.	Treatment of hepatitis delta virus infection.	USA	17655470	18-MAY-2022	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
71.	Treatment of hepatitis delta virus infection.	European Union	15865819.5	03-DEC-2015	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
72.	Treatment of hepatitis delta virus infection.	Japan	2020-152721	11-SEP-2020	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
73.	Treatment of hepatitis delta virus infection.	USA	17197687	10-MAR-2021	David Cory et al	Eiger BioPharmaceuticals, Inc.	Pending
74.	Treatment of hepatitis delta virus infection with interferon lambda.	Australia	2019325693	16-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
75.	Treatment of hepatitis delta virus infection with interferon lambda.	Brazil	BR112021003 204-5	22-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
76.	Treatment of hepatitis	Canada	3109955	17-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending

2 EP3137078 has been validated or is in the process of being validated in the following countries: Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Latvia, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, and Turkey.

3 EP3370723 has been validated or is in the process of being validated in the following countries: Belgium, Bulgaria, Switzerland, Cyprus, Czechia, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hungary, Italy, and Romania.

No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
	delta virus infection with interferon lambda.						
77.	Treatment of hepatitis delta virus infection with interferon lambda.	China	201980055328.40	23-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
78.	Treatment of hepatitis delta virus infection with interferon lambda.	Eurasia	202190594	22-MAR-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
79.	Treatment of hepatitis delta virus infection with interferon lambda.	European Union	19853099.0	22-MAR-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
80.	Treatment of hepatitis delta virus infection with interferon lambda.	India	202117012318	22-MAR-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
81.	Treatment of hepatitis delta virus infection with interferon lambda.	Israel	280869	15-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
82.	Treatment of hepatitis delta virus infection with interferon lambda.	Japan	2021-510076	22-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
83.	Treatment of hepatitis delta virus infection with interferon lambda.	Mexico	MX/A/2021/002147	23-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
84.	Treatment of hepatitis delta virus infection with interferon lambda.	S. Africa	2021/01370	26-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
85.	Treatment of hepatitis delta virus infection with interferon lambda.	S. Korea	10-2021-7008138	18-MAR-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
86.	Treatment of hepatitis delta virus infection with interferon lambda.	USA	17268657	17-FEB-2021	Ingrid Choong et al	Eiger BioPharmaceuticals, Inc.	Pending
87.	Treatment of hepatitis delta virus infection with interferon lambda.	China	201780020097.4	17-FEB-2017	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Pending
88.	Treatment of hepatitis delta virus infection with interferon lambda.	European Union <sup>4</sup>	EP341667517753966.5	24-MAR-202117-FEB-2017	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Granted
89.	Treatment of hepatitis delta virus infection with interferon lambda.	European Union	21164362.2	23-MAR-2021	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Pending
90.	Treatment of hepatitis delta virus infection with interferon lambda.	Japan	2018-543599	17-FEB-2017	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Pending
91.	Treatment of hepatitis delta virus infection with interferon lambda.	S. Korea	10-2018-7026586	17-FEB-2017	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Pending

<sup>4</sup> EP3416675 has been validated or is in the process of being validated in the following countries: Albania, Austria, Belgium, Bulgaria, Switzerland, Liechtenstein, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Greece, Croatia, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, Republic of Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Sweden, Slovenia, Slovakia, San Marino, Turkey, and the United Kingdom.

No.	Title	Country	Patent no. App. no.	Issue Date/ App. Date	Inventor(s)	Current Owner	Status
92.	Treatment of hepatitis delta virus infection with interferon lambda.	USA	10953072 15999239	23-MAR-2021 17-AUG-2018	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Granted
93.	Treatment of hepatitis delta virus infection with interferon lambda.	USA	17178424	18-FEB-2021	Eduardo Bruno Martins	Eiger BioPharmaceuticals, Inc.	Pending
94.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives.	USA	10653753 16081578	19-MAY-2020 31-AUG-2018	Xiaofeng, Xiong	Eiger BioPharmaceuticals, Inc.	Granted
95.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives.	USA	11116820 16852192	14-SEP-2021 17-APR-2020	Xiaofeng, Xiong	Eiger BioPharmaceuticals, Inc.	Granted
96.	Compositions of Exendin-4 derivatives. (Treatment of hyperinsulinemia hypoglycemia with exendin-4 derivatives.)	USA	17398551	10-AUG-2021	Xiaofeng, Xiong	Eiger BioPharmaceuticals, Inc.	Pending
97.	Treatment of tuberous sclerosis complex.	USA	63212931	21-JUN-2021	David Apelian et al	Eiger BioPharmaceuticals, Inc.	Pending
98.	Treatment of congenital hyperinsulinism with avexitide.	USA	63213051	21-JUN-2021	Colleen M. Craig	Eiger BioPharmaceuticals, Inc.	Pending

EXHIBIT C

**TRADEMARKS**

No.	Mark	Country	App. No./ App. Date	Reg. No./ Reg. Date	Current Owner	Status
1.	EIGER ONE CARE	European Union	018289845 17-Aug-20	018289845 23-Dec-20	Eiger BioPharmaceuticals, Inc.	Registered
2.	EIGER ONE CARE	United Kingdom	UK00918289845 17-Aug-20	UK00918289845 23-Dec-20	Eiger BioPharmaceuticals, Inc.	Registered
3.	EIGER ONE CARE	USA	90112290 Aug. 13, 2020	--	Eiger BioPharmaceuticals, Inc.	Pending Intent to Use
4.	EIGER ONECARE	European Union	018289844 17-Aug-20	018289844 23-Dec-20	Eiger BioPharmaceuticals, Inc.	Registered
5.	EIGER ONECARE	United Kingdom	UK00918289844 17-Aug-20	UK00918289844 23-Dec-20	Eiger BioPharmaceuticals, Inc.	Registered
6.	EIGER ONECARE	USA	90087464 Aug. 01, 2020	6336946 Apr. 27, 2021	Eiger BioPharmaceuticals, Inc.	Registered
7.	EIGERCARE	European Union	01833990 4-May-20	01833990 5-Sep-20	Eiger BioPharmaceuticals, Inc.	Registered
8.	EIGERCARE	United Kingdom	UK00003489980 14-May-20	UK00003489980 4-Sep-20	Eiger BioPharmaceuticals, Inc.	Registered
9.	EIGERCARE	United Kingdom	UK00918233990 4-May-20	UK00918233990 5-Sep-20	Eiger BioPharmaceuticals, Inc.	Registered
10.	EIGERONECARE	European Union	018289843 17-Aug-20	018289843 23-Dec-20	Eiger BioPharmaceuticals, Inc.	Registered
11.	EIGERONECARE	United Kingdom	UK00918289843 17-Aug-20	UK00918289843 23-Dec-20	Eiger BioPharmaceuticals, Inc.	Registered
12.	EIGERONECARE	USA	90087462 Aug. 01, 2020	6336945 Apr. 27, 2021	Eiger BioPharmaceuticals, Inc.	Registered
13.	ZOKINVY	European Union	018256186 18-Jun-20	018256186 20-Oct-20	Eiger BioPharmaceuticals, Inc.	Registered
14.	ZOKINVY	Switzerland	1543058 (IR) 24-JUN-2020	1543058 (IR) 24-JUN-2020	Eiger BioPharmaceuticals, Inc.	Registered
15.	ZOKINVY	United Kingdom	UK00918256186 18-Jun-20	UK00918256186 20-Oct-20	Eiger BioPharmaceuticals, Inc.	Registered
16.	ZOKINVY	United Kingdom	1543058 (IR) 24-JUN-2020	1543058 (IR) 24-JUN-2020	Eiger BioPharmaceuticals, Inc.	Registered
17.	ZOKINVY	USA	90005739 Jun. 17, 2020	6317378 Apr. 06, 2021	Eiger BioPharmaceuticals, Inc.	Registered